Pharmacogenomics is considered as the new frontier to predict the response to treatments and it can also be based on the comparison of family members being treated for the same condition. No data are available on the impact of anti-tumour necrosis factor (TNF)-α therapies in members of the same family with ankylosing spondylitis (AS).

Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis

C. Selmi;
2015-01-01

Abstract

Pharmacogenomics is considered as the new frontier to predict the response to treatments and it can also be based on the comparison of family members being treated for the same condition. No data are available on the impact of anti-tumour necrosis factor (TNF)-α therapies in members of the same family with ankylosing spondylitis (AS).
2015
Adolescent; Adult; Age Factors; Aged; Female; Genotype; HLA-B27 Antigen; Humans; Immunosuppressive Agents; Middle Aged; Pedigree; Pharmacogenetics; Phenotype; Remission Induction; Severity of Illness Index; Spondylitis; Ankylosing; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; Mothers
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/1107
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact